Pitkäniemi J, Seppä K, Hakama M, Malminiemi O, Palva T, Vuoristo M-S, Järvinen H, Paimela H, Pikkarainen P, Anttila A, Elovainio L, Hakulinen T, Karjalainen S, Pylkkänen L, Rautalahti M, Sarkeala T, Vertio H, Malila N
Finnish Cancer Registry, Institute for Statistical and Epidemiological Cancer Research , Helsinki , Finland ; Department of Public Health , University of Helsinki , Finland.
Finnish Cancer Registry, Institute for Statistical and Epidemiological Cancer Research , Helsinki , Finland.
BMJ Open Gastroenterol. 2015 Jun 8;2(1):e000034. doi: 10.1136/bmjgast-2015-000034. eCollection 2015.
Screening for colorectal cancer (CRC) with guaiac-based faecal occult-blood test (FOBT) has been reported to reduce CRC mortality in randomised trials in the 1990s, but not in routine screening, so far. In Finland, a large randomised study on biennial FOB screening for CRC was gradually nested as part of the routine health services from 2004. We evaluate the effectiveness of screening as a public health policy in the largest population so far reported.
We randomly allocated (1:1) men and women aged 60-69 years to those invited for screening and those not invited (controls), between 2004 and 2012. This resulted in 180 210 subjects in the screening arm and 180 282 in the control arm. In 2012, the programme covered 43% of the target age population in Finland.
The median follow-up time was 4.5 years (maximum 8.3 years), with a total of 1.6 million person-years. The CRC incidence rate ratio between the screening and control arm was 1.11 (95% CI 1.01 to 1.23). The mortality rate ratio from CRC between the screening and control arm was 1.04 (0.84 to 1.28), respectively. The CRC mortality risk ratio was 0.88 (0.66 to 1.16) and 1.33 (0.94 to 1.87) in males and females, respectively.
We did not find any effect in a randomised health services study of FOBT screening on CRC mortality. The substantial effect difference between males and females is inconsistent with the evidence from randomised clinical trials and with the recommendations of several international organisations. Even if our findings are still inconclusive, they highlight the importance of randomised evaluation when new health policies are implemented.
002_2010_august.
据报道,在20世纪90年代的随机试验中,基于愈创木脂的粪便潜血试验(FOBT)筛查结直肠癌(CRC)可降低CRC死亡率,但迄今为止在常规筛查中并未降低。在芬兰,一项关于每两年进行一次CRC FOB筛查的大型随机研究从2004年起逐步纳入常规医疗服务。我们在迄今为止报告的最大人群中评估筛查作为一项公共卫生政策的有效性。
在2004年至2012年期间,我们将年龄在60 - 69岁的男性和女性随机分配(1:1)为受邀参加筛查者和未受邀者(对照组)。这导致筛查组有180210名受试者,对照组有180282名受试者。2012年,该项目覆盖了芬兰43%的目标年龄人群。
中位随访时间为4.5年(最长8.3年),总人年数为160万。筛查组与对照组之间的CRC发病率比为1.11(95%可信区间1.01至1.23)。筛查组与对照组之间的CRC死亡率比分别为1.04(0.84至1.28)。男性和女性的CRC死亡风险比分别为0.88(0.66至1.16)和1.33(0.94至1.87)。
在一项关于FOBT筛查对CRC死亡率影响的随机医疗服务研究中,我们未发现任何效果。男性和女性之间的显著效果差异与随机临床试验的证据以及几个国际组织的建议不一致。即使我们的研究结果仍无定论,但它们凸显了实施新的卫生政策时进行随机评估的重要性。
002_2010_august